Cas9 activates the p53 pathway and selects for p53-inactivating mutations

Enache OM, Rendo V, Abdusamad M, Lam D, Davison D, Pal S, Currimjee N, Hess J, Pantel S, Nag A, et al. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat Genet. 2020;52:662–668.

NOTES

Enache, Oana MRendo, VeronicaAbdusamad, MaiLam, DanielDavison, DesireePal, SangitaCurrimjee, NaomiHess, JulianPantel, SashaNag, AnweshaThorner, Aaron RDoench, John GVazquez, FranciscaBeroukhim, RameenGolub, Todd RBen-David, UriengR01 CA188228/CA/NCI NIH HHS/R01 DA018828/DA/NIDA NIH HHS/R01 CA215489/CA/NCI NIH HHS/R01 CA219943/CA/NCI NIH HHS/K08 CA122833/CA/NCI NIH HHS/HHMI/Howard Hughes Medical Institute/Research Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov'tNat Genet. 2020 Jul;52(7):662-668. doi: 10.1038/s41588-020-0623-4. Epub 2020 May 18.

Abstract

Cas9 is commonly introduced into cell lines to enable CRISPR-Cas9-mediated genome editing. Here, we studied the genetic and transcriptional consequences of Cas9 expression itself. Gene expression profiling of 165 pairs of human cancer cell lines and their Cas9-expressing derivatives revealed upregulation of the p53 pathway upon introduction of Cas9, specifically in wild-type TP53 (TP53-WT) cell lines. This was confirmed at the messenger RNA and protein levels. Moreover, elevated levels of DNA repair were observed in Cas9-expressing cell lines. Genetic characterization of 42 cell line pairs showed that introduction of Cas9 can lead to the emergence and expansion of p53-inactivating mutations. This was confirmed by competition experiments in isogenic TP53-WT and TP53-null (TP53(-/-)) cell lines. Lastly, Cas9 was less active in TP53-WT than in TP53-mutant cell lines, and Cas9-induced p53 pathway activation affected cellular sensitivity to both genetic and chemical perturbations. These findings may have broad implications for the proper use of CRISPR-Cas9-mediated genome editing.
Last updated on 02/17/2021